Carcinoma, Small Cell Clinical Trial
Official title:
A Phase I/II Study of Radiation Dose Intensity Concurrent With Chemotherapy For Limited Stage Small Cell Lung Cancer
Verified date | October 2011 |
Source | AHS Cancer Control Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Health Canada |
Study type | Interventional |
Patients who have limited stage small cell lung cancer are presently treated with chemotherapy and radiation therapy (RT). Despite this aggressive treatment the vast majority of patients will have their cancer recur after treatment. A recurrence is not curable at this time, therefore efforts to reduce recurrence rates are desirable. Due to the sensitivity of surrounding structures in the chest to radiation, it has not been possible to give doses that can cure most tumours. Three-dimensional conformal radiotherapy is a special form of radiation therapy that allows doctors to reduce the amount of radiation dose to normal tissues and therefore reduce toxicity and in turn, let them safely increase the dose to tumours. The purpose of this study is to determine whether the combination of three-dimensional conformal radiotherapy and chemotherapy will be a more effective treatment. If the treatment is found to be safe for the first group of patients, then the total radiation dose will be increased for the next group of patients who are treated on this study.
Status | Completed |
Enrollment | 18 |
Est. completion date | October 2007 |
Est. primary completion date | September 2007 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically proven small cell lung cancer - Age equal to or greater than 18 years - Good performance status - Signed study consent form Exclusion Criteria: - Patients who have undergone resection - Wrong histology - Previous thoracic/neck radiotherapy - Prior chemotherapy - Previous ME within 6 months - Pregnant - Tumour too large to irradiate safely |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Cross Cancer Institute | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
AHS Cancer Control Alberta | Cross Cancer Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | grade 3 RT toxicity rate | |||
Secondary | disease free | |||
Secondary | overall survival |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01860898 -
A Phase I Study of iPS Cell Generation From Patients With COPD
|
N/A | |
Completed |
NCT00046787 -
Efficacy and Safety Study of OSI-211 (Liposomal Lurtotecan) to Treat Recurrent Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT03212404 -
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
|
Phase 1 | |
Recruiting |
NCT03554473 -
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
|
Phase 1/Phase 2 | |
Terminated |
NCT00094978 -
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
|
Phase 1 | |
Recruiting |
NCT04162041 -
Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT03092739 -
A Study to Assess Programmed Death Ligand-1 (PD-L1) Expression in Cytological Versus Histological Lung Cancer Specimens
|
||
Completed |
NCT00305942 -
Topotecan and Carboplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT00324558 -
Adjuvant BEmiparin in Small Cell Lung Carcinoma (ABEL STUDY)
|
Phase 2 | |
Completed |
NCT00359359 -
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00191750 -
A Study of Pemetrexed in Small Cell Lung Cancer, Which Has Returned
|
Phase 2 | |
Recruiting |
NCT05461430 -
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
|
||
Recruiting |
NCT02366741 -
Neurocognitive Function After Prophylactic Cranial Irradiation & Hippocampal Sparing in LD SCLC Patients - a Pilot Study
|
N/A | |
Active, not recruiting |
NCT01900951 -
Temozolomide as Maintenance Therapy in Small Cell Lung Cancer
|
Phase 2 | |
Completed |
NCT00826644 -
Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer Patient
|
Phase 3 | |
Completed |
NCT00284154 -
Vinflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT00100256 -
Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
|
Phase 1/Phase 2 | |
Terminated |
NCT02034123 -
Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma
|
Phase 1 | |
Recruiting |
NCT05500391 -
Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
|
Phase 2 | |
Recruiting |
NCT02688036 -
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
|
Phase 3 |